Behçet's Disease

I. Introduction

Behçet's disease (BD) is a chronic, relapsing, multi-systemic inflammatory disorder characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. It is a form of systemic vasculitis, and while it can affect individuals of any age, its onset frequently occurs in young adults and adolescents. While classic BD manifestations may be readily recognized, incomplete presentations and the relative rarity of the disease can pose diagnostic challenges, particularly in pediatric populations. Given the gastrointestinal involvement that can occur in BD, pediatric gastroenterologists play a crucial role in diagnosis and management.

II. Epidemiology

• Global Distribution: BD is more prevalent in countries along the ancient Silk Road, including Turkey, the Middle East, and East Asia (especially Japan, Korea, and China). This geographic distribution suggests a complex interplay of genetic and environmental factors.
• Prevalence: The prevalence varies widely, ranging from <1/100,000 in North America and Northern Europe to >100/100,000 in Turkey.
• Age of Onset: While BD can occur at any age, the typical age of onset is between 20 and 40 years. However, pediatric-onset BD accounts for approximately 10-25% of all cases. Pediatric cases are defined by disease onset before the age of 16 years.
• Sex Distribution: In most adult populations, BD is more common in males than in females. However, in some pediatric cohorts, the sex distribution is nearly equal, or even slightly more common in females.
• Ethnicity: BD is more common in individuals of Turkish, Middle Eastern, and East Asian descent. However, it can occur in individuals of all ethnicities.

III. Pathogenesis

The precise pathogenesis of BD remains incompletely understood, but it is believed to involve a complex interplay of genetic predisposition, environmental triggers, and dysregulation of the immune system. Key aspects include:

• Genetic Factors:
  • HLA-B51: The strongest genetic association is with the HLA-B51 allele, a class I major histocompatibility complex (MHC) antigen. However, HLA-B51 is not universally present in all BD patients (its prevalence varies geographically), and many individuals with HLA-B51 never develop BD. This highlights the importance of other genetic and environmental factors. The HLA-B51 allele is found in approximately 50-80% of individuals with Behcet's.
  • Other Genetic Associations: Genome-wide association studies (GWAS) have identified numerous other non-HLA genes associated with BD, including genes involved in immune regulation (e.g., IL23R, IL10, STAT4).
• Environmental Triggers:
  • Infectious Agents: Several infectious agents have been implicated as potential triggers for BD, including Streptococcus sanguinis and herpes simplex virus (HSV). However, a definitive causal relationship has not been established.
  • Other Environmental Factors: Other potential environmental triggers include heavy metals and certain medications.
• Immune Dysregulation:
  • Innate Immunity: Dysregulation of the innate immune system appears to play a central role in BD pathogenesis. Neutrophils are hyperactive in BD patients, exhibiting increased chemotaxis, phagocytosis, and reactive oxygen species production. Macrophages and natural killer (NK) cells are also implicated.
  • Adaptive Immunity: Both CD4+ T helper cells and CD8+ cytotoxic T cells are involved in BD. Th1 and Th17 responses are thought to be particularly important. IL-17, produced by Th17 cells, promotes neutrophil recruitment and inflammation.
  • Vasculitis: The hallmark of BD is a vasculitis affecting vessels of all sizes, although small vessels are most commonly involved. Endothelial cell activation and damage contribute to the inflammatory process.

IV. Clinical Manifestations

BD is a multi-systemic disease, meaning it can affect multiple organ systems. The classic triad of symptoms is oral ulcers, genital ulcers, and uveitis. However, not all patients present with the complete triad.

• Mucocutaneous Manifestations:
  • Oral Ulcers: Recurrent, painful oral ulcers are the most common manifestation of BD, occurring in nearly all patients. They are typically aphthous-like, round or oval, with a white or yellow base and a red halo. They can occur anywhere in the oral cavity but are most common on the buccal mucosa, tongue, and lips.
  • Genital Ulcers: Similar to oral ulcers, genital ulcers are recurrent and painful. In males, they typically occur on the scrotum or penis. In females, they can occur on the labia majora, labia minora, or vagina.
  • Skin Lesions: A variety of skin lesions can occur, including:
    • Erythema Nodosum-like Lesions: Painful, red, raised nodules, typically on the lower extremities.
    • Papulopustular Lesions: Acneiform lesions, folliculitis, or superficial thrombophlebitis.
    • Pathergy Reaction: An exaggerated inflammatory response to minor trauma, such as a needle prick. This is a characteristic feature of BD, although its sensitivity and specificity are variable.
• Ocular Manifestations:
  • Uveitis: Uveitis is a common and potentially sight-threatening manifestation of BD. It can be anterior, posterior, or panuveitis. Recurrent episodes of uveitis can lead to complications such as glaucoma, cataracts, and blindness.
• Vascular Manifestations:
  • Arterial Involvement: Arterial involvement can lead to aneurysms, occlusions, or thrombosis. Aneurysms are most common in the pulmonary arteries and aorta.
  • Venous Involvement: Venous involvement can lead to superficial thrombophlebitis or deep vein thrombosis (DVT). Cerebral venous sinus thrombosis is a serious complication.
• Neurological Manifestations:
  • Neuro-Behçet's Disease (NBD): Neurological involvement can manifest as:
    • Parenchymal NBD: Characterized by brainstem lesions, cerebral lesions, or spinal cord involvement. Can lead to headaches, seizures, cognitive dysfunction, or motor deficits.
    • Non-Parenchymal NBD: Characterized by cerebral venous sinus thrombosis or aseptic meningitis.
• Gastrointestinal Manifestations:
  • Intestinal Ulcerations: Gastrointestinal involvement occurs in a subset of BD patients, particularly those from East Asia. Ulcerations can occur anywhere in the GI tract, but are most common in the ileocecal region. These ulcerations can cause abdominal pain, diarrhea, bleeding, perforation, and stricture formation. It can mimic Crohn's disease. (See table 1 below)
    
  • Esophageal Ulcers: Less common, but can cause dysphagia or odynophagia.
  • Other GI Manifestations: Less common manifestations include pancreatitis, liver involvement (rare), and protein-losing enteropathy.
• Musculoskeletal Manifestations:
  • Arthritis: Non-erosive, oligoarticular arthritis, typically affecting large joints of the lower extremities.
  • Arthralgias: Joint pain without objective signs of inflammation.
• Pulmonary Manifestations:
  • Pulmonary Artery Aneurysms: Can lead to hemoptysis, dyspnea, or sudden death.
  • Pulmonary Thrombosis: Less common.

V. Diagnosis

Diagnosing BD can be challenging, particularly in pediatric patients, as there is no single pathognomonic test. Diagnosis relies on a combination of clinical findings, exclusion of other conditions, and adherence to established diagnostic criteria.

• International Criteria for Behçet's Disease (ICBD): The most widely used criteria are the ICBD, which assign points to various clinical manifestations. A score of ≥4 is considered diagnostic. The ICBD criteria include:
  • Oral aphthosis (2 points)
  • Genital aphthosis (2 points)
  • Ocular lesions (2 points)
  • Skin lesions (1 point)
  • Neurologic manifestations (1 point)
  • Vascular manifestations (1 point)
  • Positive pathergy test (1 point)
• Diagnostic Challenges in Children: Pediatric patients may present with incomplete or atypical manifestations of BD, making diagnosis more difficult.
• Differential Diagnosis: The differential diagnosis of BD is broad and includes:
  • Aphthous stomatitis
  • Herpes simplex infection
  • Crohn's disease
  • Ulcerative colitis
  • Reactive arthritis
  • Systemic lupus erythematosus (SLE)
  • Vasculitis (e.g., granulomatosis with polyangiitis, microscopic polyangiitis)
  • Familial Mediterranean Fever (FMF)
• Laboratory Investigations:
  • Complete Blood Count (CBC): May show leukocytosis or thrombocytosis during active disease.
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Elevated during active inflammation.
  • HLA-B51 Typing: Helpful, but not diagnostic, as HLA-B51 is not universally present in BD patients.
  • Other Autoimmune Markers: ANA, anti-dsDNA, ANCA should be negative (to rule out other autoimmune or vasculitic conditions).
  • Stool Studies: Rule out infectious causes of diarrhea if GI symptoms are present.
  • Endoscopy and Colonoscopy: With biopsy, may be necessary to evaluate gastrointestinal ulcerations and rule out Crohn's disease or other inflammatory bowel diseases.
• Imaging Studies:
  • CT Angiography or MRI Angiography: To evaluate for vascular involvement (aneurysms, thrombosis).
  • MRI of the Brain: To evaluate for neurological involvement (parenchymal lesions, cerebral venous sinus thrombosis).
  • Abdominal CT or MRI: To evaluate for gastrointestinal involvement (ulcerations, thickening of the bowel wall).

VI. Treatment

The treatment of BD is tailored to the individual patient and depends on the severity and location of the disease manifestations. The goals of treatment are to reduce inflammation, prevent organ damage, and improve quality of life.

• General Principles:
  • Multidisciplinary Approach: Management requires a multidisciplinary approach involving gastroenterologists, rheumatologists, ophthalmologists, neurologists, and other specialists.
  • Individualized Treatment: Treatment should be tailored to the specific manifestations and severity of the disease in each patient.
  • Step-Up Approach: Treatment typically starts with less aggressive therapies and escalates as needed.
• Pharmacologic Therapies:
  • Topical Corticosteroids: For oral and genital ulcers.
  • Colchicine: Effective for mucocutaneous manifestations, particularly oral and genital ulcers, and erythema nodosum. Also has some efficacy in preventing arthritis.
  • Systemic Corticosteroids: Prednisone or methylprednisolone, used for more severe manifestations, such as uveitis, neurological involvement, and severe gastrointestinal disease. Used for acute flares.
  • Immunosuppressants:
    • Azathioprine: A purine analog that inhibits T cell proliferation. Effective for mucocutaneous manifestations, uveitis, and arthritis. First line option.
    • Methotrexate: A folate antagonist that inhibits T cell activation. Effective for mucocutaneous manifestations and arthritis.
    • Cyclosporine: A calcineurin inhibitor that suppresses T cell activation. Primarily used for severe uveitis.
    • Cyclophosphamide: A potent immunosuppressant used for life-threatening manifestations, such as pulmonary artery aneurysms or severe neurological involvement.
  • Biologic Agents:
    • TNF-alpha Inhibitors (Infliximab, Adalimumab, Etanercept): Effective for mucocutaneous manifestations, uveitis, and arthritis. Infliximab has also been shown to be effective for gastrointestinal involvement. Commonly used when traditional immunosuppressants fail or are not tolerated.
    • Interleukin-1 Inhibitors (Anakinra, Canakinumab): Anakinra has shown promise in some cases of BD, particularly for mucocutaneous and articular manifestations.
    • Apremilast: A phosphodiesterase-4 inhibitor approved for oral ulcers in BD.
    • Interleukin-6 Inhibitors (Tocilizumab): Being investigated for use in refractory cases.
  • Other Medications:
    • Thalidomide: Effective for oral ulcers, but its use is limited by its teratogenic potential.
    • Pentoxifylline: May improve mucocutaneous manifestations and vascular complications.
• Management of Specific Manifestations:
  • Uveitis: Requires prompt and aggressive treatment to prevent vision loss. Topical corticosteroids, systemic corticosteroids, immunosuppressants (azathioprine, cyclosporine), and TNF-alpha inhibitors may be used.
  • Vascular Involvement: Requires anticoagulation (for thrombosis) or immunosuppression/surgical intervention (for aneurysms).
  • Neurological Involvement: Requires high-dose corticosteroids, immunosuppressants (cyclophosphamide, azathioprine), and/or TNF-alpha inhibitors.
  • Gastrointestinal Involvement: Corticosteroids, immunosuppressants (azathioprine, methotrexate), and TNF-alpha inhibitors (especially infliximab) are used. Surgical resection may be necessary for complications such as perforation or stricture.
• Special Considerations in Children:
  • Growth and Development: Corticosteroids can have significant effects on growth and development. The lowest effective dose should be used, and alternative therapies should be considered when possible.
  • Vaccinations: Immunosuppressive medications can impair the immune response to vaccines. Live vaccines should be avoided. Inactivated vaccines should be given when possible, but the response may be suboptimal.
  • Transition of Care: As pediatric patients with BD transition to adult care, it is important to ensure continuity of care and ongoing monitoring.

VII. Prognosis

The prognosis of BD is variable and depends on the severity and location of the disease manifestations, as well as the response to treatment.

• Factors Influencing Prognosis:
  • Age of Onset: Pediatric-onset BD may be associated with a more severe disease course.
  • Organ Involvement: Involvement of the eyes, central nervous system, or large vessels is associated with a poorer prognosis.
  • Genetic Factors: HLA-B51 positivity may be associated with a more severe disease course in some populations.
  • Treatment Adherence: Adherence to treatment is crucial for preventing disease flares and organ damage.
• General Outcomes:
  • Mortality: Mortality is rare in BD, but can occur as a result of complications such as pulmonary artery aneurysms, neurological involvement, or gastrointestinal perforation.
  • Morbidity: BD can lead to significant morbidity, including blindness, neurological deficits, chronic pain, and gastrointestinal dysfunction.
  • Remission: Some patients may experience periods of remission, while others have a chronic, relapsing course.

Patients with BD require long-term monitoring for disease activity and complications. This includes regular ophthalmologic examinations, neurological assessments, and imaging studies as needed.

VIII. Conclusion

Behçet's disease is a complex, multi-systemic inflammatory disorder that can present significant diagnostic and therapeutic challenges, particularly in pediatric patients. Pediatric gastroenterologists play a critical role in the diagnosis and management of BD, especially in cases with gastrointestinal involvement. A thorough understanding of the epidemiology, pathogenesis, clinical manifestations, diagnosis, treatment, and prognosis of BD is essential for providing optimal care to these patients. A multidisciplinary approach, individualized treatment plans, and long-term monitoring are key to improving outcomes and quality of life for children with Behçet's disease.

Table 1: Crohn's Disease vs. Behçet's Disease